學名藥企業的分析 是由出版商Espicom Business Intelligence在Issues / Year: 4所出版的。
這份英文資訊服務價格從美金1950起跳。
由於主要醫藥品專利即將到期，以及政治環境的完備
，未來不僅會有許多企業及投資家會重新評估學名藥部門的定位，大眾對學名藥市場的關心也會逐漸高漲。
在最尖端醫療市場的商業調查分析上，極受好評的市調公司 Espicom Business Intelligence（總公司：英國），整體地調查與分析各季學名藥企業，並提供英文年度情報服務 "Generic Companies Analysis" 。
此服務提供各季有關主要學名藥企業的概要、財務業績、最新企業間合作、ANDA訴訟、開發中、申請中及市場發展製品的相關資訊等。
＜架構＞
企業概要
財務業績
製品
- 有關市場發展中的製品系列、新商品及藥品申請、市場展開的最新資訊
ANDA（簡式新藥申請）
- 依各季及企業類別將美國學名藥市場的主要ANDA清單化
主要開發
- M＆A、企業間合作與訴訟等、對主要企業造成影響的複雜問題說明
＜調查對象企業一例＞
- Alpharma
- Andrx Corporation
- Apotex
- Aspen Pharmacare
- Barr Laboratories
- CIPLA
- Dr Reddy' s
- EGIS
- EON Labs
- Hexal AG
- IVAX Corp
- KRKA
- Lannett
- Lek
- Merck Generics
- Mylan Labos
- Perrigo
- Pliva
- ratiopharm
- Gedeon Richter
- Sandoz
- 藤井製藥
- Stada Arzneimittel
- Teva Pharmaceutical Industries
- Watson Pharmaceuticals
- Zentiva
- Zydus Cadila
Abstract
The easy and cost effective way to monitor developments in leading generic drug industry players.
A market of increasing significance
Interest in the generic pharmaceutical market continues to grow apace. On the back of the industry's increasingly strong market position - driven by favourable political environments and the number of medicines losing patent protection - industry and investors are re-evaluating the role the generics sector will play in the pharmaceutical industry of the future.
For many, the generics market is coming of age. No longer just a peripheral provider of low cost basic medicines, the ethical industry, investment community and the generic manufacturers themselves are waking up to the trends which are transforming the generics sector, and the increasingly important role emerging markets are playing in it.
Key company analysis Generic Companies Analysis (GCA) from Espicom is packed with facts, figures and statistics, providing you with the most thorough ongoing monitoring of the important generic companies. From financial performance to litigation, no other service provides such comprehensive insight to the companies driving growth in this rapidly expanding area of the pharmaceutical industry.
GCA: published quarterly to keep you in touch GCA company reports are updated and issued every quarter. This ongoing monitoring and regular delivery ensures that developments are incorporated into the relevant reports. This vigilance ensures that whether it's the latest deals, ANDAs, alliances or litigation you can assess the impact of the development in the context of the company, its competitors and the broader market.
Use GCA to:
- Evaluate the competitive operating environment.
- Identify which companies are applying for ANDAs, and for what.
- Understand generic companies' product line up.
- Monitor the financial performance of leading generics players.
- Track the twists and turns of litigation.
- Stay in touch with the latest M&A and strategic alliances.
Unbeatable Content
Executive commentary
Easy to read snapshots of the company highlights.
Financial performance
The most recent quarterly and annual financial results. Comparative figures, charts and a detailed review of the data allows you to track a company's progress.
Products
A review of the company's active products line-up, with regular updates on new products, approvals and launches - all put into their competitive context.
ANDAs
ANDAs in the all important US generic market are listed by company each quarter.
Major developments
M&A activity and strategic alliances and Litigation. Understand fully the dynamic and complex issues affecting the business of leading generic industry players.
Leading companies covered
- Actavis
- Andrx
- Apotex
- Aspen Pharmacare
- Barr Laboratories
- CIPLA
- Dr Reddy's
- EGIS
- Gedeon Richter
- KRKA Lannett
- Lek
- Mayne Pharma
- Merck Generics
- Mylan Labs
- Perrigo
- Pliva
- Ranbaxy
- ratiopharm
- Sandoz Sawai
- Stada Arzneimittel
- TEVA Pharmaceutical Industries
- Watson Pharmaceuticals
- Winthrop Pharmaceuticals
- Wockhardt
- Zentiva
- Zydus Cadila
Ranbaxy Laboratories
- EXECUTIVE SUMMARY.
- INTRODUCTION
- Subsidiaries of Ranbaxy, 2004
- PRODUCTS
- International Regulatory Findings and Approvals, January - December 2003
- Anda Approvals, 2003-2004.
- Top 10 selling Ranbaxy products
- Global markets
- FINANCIAL RESULTS
- Latest Yearly Results
- Financial results 2000-2003 (Rs, millions)
- Financial Results, 1996-2003, (Rs, million)
- Breakdown of expenses, 2003
- Latest Quarterly Results
- Ranbaxy Laboratories: second quarter 2004 results
- Ranbaxy Laboratories: second quarter 2004 revenue breakdown
- Ranbaxy Laboratories: mid-year 2004 results
- Ranbaxy Laboratories: mid-year 2004 revenue breakdown
- MAJOR DEVELOPMENTS
- Mergers, acquisitions and agreements
- CONTACT DETAILS
